Measuring the cost-effectiveness of cancer care.
Historically, new therapeutic strategies for cancer have been evaluated on the basis of safety and clinical efficacy. However, the current national emphasis on efficiency of resource allocation has led to the inclusion of economic assessments in oncology studies. Economic assessments measure patients' health status and resource consumption associated with a therapeutic strategy, and combine these in a cost-effectiveness analysis. Study design can include prospective analysis of clinical trials, retrospective analysis of a clinical trial or administrative databases, or a decision analytic model. Economic analysis is being used increasingly in oncology and will continue to provide meaningful data to assist clinicians in determining the optimal treatment strategies for cancer patients and to help inform health policy decision-makers about the importance of specific cancer therapeutic strategies.
Schulman
K A
KA
Division of General Internal Medicine, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.
Yabroff
K R
KR
D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D008962:Models, Theoretical; D009369:Neoplasms / Q000191:economics* / Q000628:therapy; D011446:Prospective Studies; D011788:Quality of Life; D012189:Retrospective Studies; D014481:United States